Published in Mol Ther on February 03, 2006
Targeting the RB-pathway in cancer therapy. Clin Cancer Res (2010) 1.54
RB1 dual role in proliferation and apoptosis: cell fate control and implications for cancer therapy. Oncotarget (2015) 1.20
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 5.82
Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell (2002) 5.69
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol (2005) 4.03
Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res (2004) 2.90
Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. J Clin Oncol (2007) 2.62
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol (2004) 2.44
Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment. Lung Cancer (2008) 2.37
Analysis of the H19ICR insulator. Mol Cell Biol (2007) 2.29
MicroRNA miR-199a* regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2). J Biol Chem (2008) 2.28
Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol (2011) 2.09
The H-Invitational Database (H-InvDB), a comprehensive annotation resource for human genes and transcripts. Nucleic Acids Res (2007) 2.07
Peroxiredoxin II is essential for sustaining life span of erythrocytes in mice. Blood (2003) 2.05
Chemotherapy use and associated factors among cancer patients near the end of life. Oncology (2007) 1.80
Discrepancies among patients, family members, and physicians in Korea in terms of values regarding the withholding of treatment from patients with terminal malignancies. Cancer (2004) 1.71
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res (2011) 1.69
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer (2007) 1.68
Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res (2005) 1.63
Integrative analysis of multiple gene expression profiles applied to liver cancer study. FEBS Lett (2004) 1.63
Therapeutic applications of compounds in the Magnolia family. Pharmacol Ther (2011) 1.61
Inflammation and Alzheimer's disease. Arch Pharm Res (2010) 1.60
Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer (2012) 1.58
Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch Pharm Res (2010) 1.55
MicroRNA-146a downregulates NFκB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res (2011) 1.54
Induction of dendritic cell maturation by β-glucan isolated from Sparassis crispa. Int Immunopharmacol (2010) 1.53
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res (2006) 1.53
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer (2005) 1.52
Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol (2011) 1.50
Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). Oncologist (2014) 1.50
Enhanced specificity of the p53 family proteins-based adenoviral gene therapy in uterine cervical cancer cells with E2F1-responsive promoters. Cancer Biol Ther (2006) 1.46
Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res (2008) 1.45
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation. J Thorac Oncol (2015) 1.44
Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. Cancer Res (2007) 1.43
Palliative chemotherapy for pulmonary pleomorphic carcinoma. Lung Cancer (2007) 1.40
The clinical features, management and prognosis of primary and secondary indolent lymphoma of the bone: a retrospective study of the International Extranodal Lymphoma Study Group (IELSG #14 study). Leuk Lymphoma (2014) 1.40
The anti-aging gene KLOTHO is a novel target for epigenetic silencing in human cervical carcinoma. Mol Cancer (2010) 1.39
Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol (2013) 1.39
Percutaneous cerclage wiring technique for phalangeal fractures. Tech Hand Up Extrem Surg (2014) 1.38
Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial. Jpn J Clin Oncol (2002) 1.34
Hyper innate responses in neonates lead to increased morbidity and mortality after infection. Proc Natl Acad Sci U S A (2008) 1.33
Solution structure of the CD3epsilondelta ectodomain and comparison with CD3epsilongamma as a basis for modeling T cell receptor topology and signaling. Proc Natl Acad Sci U S A (2004) 1.33
Human Fas-associated factor 1, interacting with ubiquitinated proteins and valosin-containing protein, is involved in the ubiquitin-proteasome pathway. Mol Cell Biol (2005) 1.33
JNK pathway is involved in the inhibition of inflammatory target gene expression and NF-kappaB activation by melittin. J Inflamm (Lond) (2008) 1.30
Aggressiveness of cancer-care near the end-of-life in Korea. Jpn J Clin Oncol (2008) 1.29
ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer (2007) 1.29
Genetic approach to elucidation of sasang constitutional medicine. Evid Based Complement Alternat Med (2009) 1.26
Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. Int J Oncol (2006) 1.26
Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. Oncology (2004) 1.25
Expression of NDRG2 is related to tumor progression and survival of gastric cancer patients through Fas-mediated cell death. Exp Mol Med (2007) 1.24
Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage I(E)/II(E) extranodal NK/T-cell lymphoma, nasal type. Blood (2005) 1.24
Anti-cancer effect of bee venom in prostate cancer cells through activation of caspase pathway via inactivation of NF-κB. Prostate (2010) 1.23
Expression and regulation of NDRG2 (N-myc downstream regulated gene 2) during the differentiation of dendritic cells. FEBS Lett (2003) 1.23
Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer (2012) 1.23
Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation. Lung Cancer (2012) 1.21
Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. Carcinogenesis (2009) 1.21
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol (2013) 1.20
Collagen triple helix repeat containing 1 (CTHRC1) acts via ERK-dependent induction of MMP9 to promote invasion of colorectal cancer cells. Oncotarget (2014) 1.20
A novel adipokine CTRP1 stimulates aldosterone production. FASEB J (2008) 1.20
Characterization of DNA methylation change in stem cell marker genes during differentiation of human embryonic stem cells. Biochem Biophys Res Commun (2007) 1.19
Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol Appl Pharmacol (2011) 1.19
Synthesis and biological evaluation of rhodanine derivatives as PRL-3 inhibitors. Bioorg Med Chem Lett (2006) 1.19
NDRG2 suppresses cell proliferation through down-regulation of AP-1 activity in human colon carcinoma cells. Int J Cancer (2009) 1.18
Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun (2005) 1.18
Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology (2006) 1.18
Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer (2011) 1.17
Berberine-induced AMPK activation inhibits the metastatic potential of melanoma cells via reduction of ERK activity and COX-2 protein expression. Biochem Pharmacol (2011) 1.17
The role of PET/CT in detection of gastric cancer recurrence. BMC Cancer (2009) 1.16
Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res (2009) 1.15
The attitudes of cancer patients and their families toward the disclosure of terminal illness. J Clin Oncol (2004) 1.15
Human microRNA-27a* targets Prf1 and GzmB expression to regulate NK-cell cytotoxicity. Blood (2011) 1.15
Increasing trend of isolation of non-tuberculous mycobacteria in a tertiary university hospital in South Korea. Tuberc Respir Dis (Seoul) (2012) 1.15
Genetic Effects of FTO and MC4R Polymorphisms on Body Mass in Constitutional Types. Evid Based Complement Alternat Med (2011) 1.14
Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB. Eur J Pharmacol (2010) 1.14
Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res (2002) 1.14
Evaluation of annexin II as a potential serum marker for hepatocellular carcinoma using a developed sandwich ELISA method. Int J Mol Med (2009) 1.13
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer (2007) 1.13
Bone morphogenetic protein-4 induced by NDRG2 expression inhibits MMP-9 activity in breast cancer cells. Biochem Biophys Res Commun (2009) 1.12
Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone. Jpn J Clin Oncol (2003) 1.12
CPR or DNR? End-of-life decision in Korean cancer patients: a single center's experience. Support Care Cancer (2005) 1.12
SOCS1 induced by NDRG2 expression negatively regulates STAT3 activation in breast cancer cells. Biochem Biophys Res Commun (2007) 1.11
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment. J Neurooncol (2011) 1.11
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer (2008) 1.11
Protection against lipopolysaccharide-induced sepsis and inhibition of interleukin-1beta and prostaglandin E2 synthesis by silymarin. Biochem Pharmacol (2004) 1.10
Stimulating lymphotoxin beta receptor on the dendritic cells is critical for their homeostasis and expansion. J Immunol (2005) 1.10
DNA gyrase is involved in chloroplast nucleoid partitioning. Plant Cell (2004) 1.09
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy. Breast Cancer Res Treat (2008) 1.09
Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol (2008) 1.08
Thioredoxin modulates activator protein 1 (AP-1) activity and p27Kip1 degradation through direct interaction with Jab1. Oncogene (2004) 1.08
Hormonal activity of AIMP1/p43 for glucose homeostasis. Proc Natl Acad Sci U S A (2006) 1.08
Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer (2007) 1.08
Shifting insulator boundaries. Nat Genet (2004) 1.08
Berberine inhibits human neuroblastoma cell growth through induction of p53-dependent apoptosis. Anticancer Res (2009) 1.07